Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening.

Zammit GK, Corser B, Doghramji K, Fry JM, James S, Krystal A, Mangano RM.

J Clin Sleep Med. 2006 Oct 15;2(4):417-23.

PMID:
17557470
2.

Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration.

Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN.

BMJ. 2012 Dec 17;345:e8343. doi: 10.1136/bmj.e8343. Review.

3.

Zaleplon: a review of its use in the treatment of insomnia.

Dooley M, Plosker GL.

Drugs. 2000 Aug;60(2):413-45. Review.

PMID:
10983740
4.

Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies.

Rosenberg RP.

Ann Clin Psychiatry. 2006 Jan-Mar;18(1):49-56. Review.

PMID:
16517453
5.

Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia.

Weitzel KW, Wickman JM, Augustin SG, Strom JG.

Clin Ther. 2000 Nov;22(11):1254-67. Review.

PMID:
11117652
6.
7.

Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis.

Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T.

Hum Psychopharmacol. 2004 Jul;19(5):305-22. Review.

PMID:
15252823
8.

Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

Hesse LM, von Moltke LL, Greenblatt DJ.

CNS Drugs. 2003;17(7):513-32. Review.

PMID:
12751920
9.

New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon.

Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L.

Drug Saf. 2003;26(4):261-82. Review.

PMID:
12608888
10.

Efficacy and safety of zaleplon at peak plasma levels.

Mangano RM.

Int J Clin Pract Suppl. 2001 Jan;(116):9-13. Review.

PMID:
11219331
11.

Implications of hypnotic flexibility on patterns of clinical use.

Lader MH.

Int J Clin Pract Suppl. 2001 Jan;(116):14-9. Review.

PMID:
11219327
12.

Pharmacological interventions for sleepiness and sleep disturbances caused by shift work.

Liira J, Verbeek JH, Costa G, Driscoll TR, Sallinen M, Isotalo LK, Ruotsalainen JH.

Cochrane Database Syst Rev. 2014 Aug 12;(8):CD009776. doi: 10.1002/14651858.CD009776.pub2. Review.

PMID:
25113164
13.

Safety of zaleplon in the treatment of insomnia.

Israel AG, Kramer JA.

Ann Pharmacother. 2002 May;36(5):852-9. Review.

PMID:
11978165
14.

Management of insomnia--the role of zaleplon.

Richardson GS, Roth T, Kramer JA.

MedGenMed. 2002 Mar 14;4(1):9. Review.

15.

Benefit-risk assessment of zaleplon in the treatment of insomnia.

Barbera J, Shapiro C.

Drug Saf. 2005;28(4):301-18. Review.

PMID:
15783240
16.

Methods for the analysis of nonbenzodiazepine hypnotic drugs in biological matrices.

Tonon MA, Bonato PS.

Bioanalysis. 2012 Feb;4(3):291-304. doi: 10.4155/bio.11.313. Review.

PMID:
22303833
17.

In the Zzz zone: the effects of Z-drugs on human performance and driving.

Gunja N.

J Med Toxicol. 2013 Jun;9(2):163-71. doi: 10.1007/s13181-013-0294-y. Review.

18.

The clinical and forensic toxicology of Z-drugs.

Gunja N.

J Med Toxicol. 2013 Jun;9(2):155-62. doi: 10.1007/s13181-013-0292-0. Review.

19.

Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits.

Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE.

BMJ. 2005 Nov 19;331(7526):1169. Epub 2005 Nov 11. Review.

20.

Extended-release zolpidem: efficacy and tolerability profile.

Owen RT.

Drugs Today (Barc). 2006 Nov;42(11):721-7. Review.

PMID:
17171191

Supplemental Content

Support Center